Abstract
Tuberculosis (TB) is one of the major global health concerns. There has been a lack of an effective vaccine strategy. The Bacillus Calmette-Guerin (BCG), the only licensed vaccine against TB, is not effective against adult pulmonary TB, the highly contagious form of TB. In the past two decades or so, many novel TB vaccines have been developed, and some of them were evaluated in clinical trials. However, the lack of validated immune correlates to assess the clinical relevance of novel TB vaccines before their entry into costly efficacy trials is a huge challenge to the field of TB vaccine development. Here we describe a general protocol for the procedure of a systematic immunological approach that can be utilized to better assess the clinical relevance of TB vaccine-activated T cells in early phases of clinical studies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
WHO (2018) Global tuberculosis report. WHO, Geneva
Voss G, Casimiro D, Neyrolles O et al (2018) Progress and challenges in TB vaccine development. F1000Res 7:199
Kaufmann SHE, Dockrell HM, Drager N et al (2017) TBVAC2020: advancing tuberculosis vaccines from discovery to clinical development. Front Immunol 8:1203. https://doi.org/10.3389/fimmu.2017.01203
Xing Z, Jeyanathan M, Smaill F (2014) New approaches to TB vaccination. Chest 146:804–812
Tameris MD, Hatherill M, Landry BS et al (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381:1021–1028
Nemes E, Geldenhuys H, Rozot V et al (2018) Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med 379:138–149
Kaufmann SHE, Weiner J, von Reyn CF (2017) Novel approaches to tuberculosis vaccine development. Int J Infect Dis 56:263–267
Jeyanathan M, Yao Y, Afkhami S et al (2018) New tuberculosis vaccine strategies: taking aim at un-natural immunity. Trends Immunol 39:419–433
Li Q, Song H-Y, Ellner JJ et al (2002) Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Vaccine Immunol 9:901–907
Li Q, Hoft DF, Kampmann B et al (2002) Investigation of the relationships between immune-mediated inhibition of Mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis 186:1448–1457
Minassian AM, Satti I, Poulton ID et al (2012) A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guérin. J Infect Dis 205:1035–1042
Jeyanathan M, Damjanovic D, Yao Y et al (2016) Induction of an immune-protective t-cell repertoire with diverse genetic coverage by a novel viral-vectored tuberculosis vaccine in humans. J Infect Dis 214:1996–2005
Hoffmeister B, Kiecker F, Tesfa L et al (2003) Mapping T cell epitopes by flow cytometry. Methods 29:270–281
Peters B, Sette A, Kim Y et al (2012) Immune epitope database analysis resource. Nucleic Acids Res 40:W525–W530
Weichold FF, Mueller S, Kortsik C et al (2007) Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis. Genes Immun 8:334–343
Acknowledgments
The work is supported by funds from the Foundation Program of the Canadian Institutes of Health Research (CIHR) and the Collaborative Health Research Program of CIHR and the Natural Sciences and Engineering Research Council of Canada.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Jeyanathan, M., Xing, Z. (2020). Assessment of Immune Protective T Cell Repertoire in Humans Immunized with Novel Tuberculosis Vaccines. In: Liu, C. (eds) T-Cell Receptor Signaling. Methods in Molecular Biology, vol 2111. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0266-9_15
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0266-9_15
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0265-2
Online ISBN: 978-1-0716-0266-9
eBook Packages: Springer Protocols